Development of a sandwich ELISA for detecting 3AB non-structural protein of foot-and-mouth disease virus / 生物工程学报

Antigenic purity is important for quality control of the foot-and-mouth (FMD) whole virus inactivated vaccine. The recommended method for evaluation the antigenic purity of FMD vaccine is to check the serum conversion to non-structural protein (NSP) 3AB antibody after 2 to 3 times inoculation of animals with inactivated vaccine. In this study, we developed a quantitative ELISA to detect the amount of residual 3AB in vaccine antigen, to provide a reference to evaluate the antigenic purity of FMD vaccine. Monoclonal antibody (Mab) of NSP 3A and HRP-conjugated Mab of NSP 3B were used to establish a sandwich ELISA to quantify the NSP 3AB in vaccine antigen of FMD. Purified NSP 3AB expressed in Escherichia coli was serially diluted and detected to draw the standard curve. The detectable limit was determined to be the lowest concentration of standard where the ratio of its OD value to OD blank well was not less than 2.0. Results: The OD value was linearly corelated with the concentration of 3AB protein within the range between 4.7 and 600 ng/mL. The correlation coefficient R² is greater than 0.99, and the lowest detectable limit is 4.7 ng/mL. The amount of 3AB protein in non-purified inactivated virus antigen was detected between 9.3 and 200 ng/mL depending on the 12 different virus strains, whereas the amount of 3AB in purified virus antigen was below the lowest detectable limit. The amount of 3AB in 9 batches of commercial FMD vaccine antigens was between 9.0 and 74 ng/mL, whereas it was below the detectable limit in other 24 batches of commercial vaccine antigens. Conclusion: the sandwich ELISA established in this study is specific and sensitive to detect the content of 3AB protein in vaccine antigen of FMD, which will be a useful method for evaluation of the antigenic purity and quality control of FMD inactivated vaccine.

Molecular characteristics of serogroup B neisseria meningitidis, China / 中华预防医学杂志

Objective@#To investigate the molecular characteristics of serogroup B neisseria meningitidis in China.@*Methods@#Total of 485 (100 strains isolated from cerebrospinal fluid or blood samples of encephalomyelitis cases, and 385 strains isolated from nasopharynx of healthy carriers) Meningococcal serogroup B (MenB) strains, isolated from 29 provinces of China between 1968 and 2016, were analyzed by multilocus sequence typing (MLST) and PorA typing methods. Further, the genetic diversity of three MenB vaccine proteins, FHbp, NadA and NHBA, were analyzed.@*Results@#The 485 study strains belonged to 270 sequence types (STs), 107 of which (representing 211 strains) could be grouped into ten clonal complexes (CC). CC4821 has been the predominant lineage in China since 2005 (28.7%, n=139). The most common PorA types of MenB strains from invasive meningococcal cases were P1.5-2,2-2 (10.0%, n=10), P1.5-1,2-2 (9.0%, n=9) and P1.5-1,10-4 (9.0%, n=9). Four hundred and twenty one strains had intact fhbp gene; variant 1, 2 and 3 accounted for 12.8% (54 strains), 85.0% (358 strains) and 2.2% (9 strains) respevtively. Ten out of 432 strains (2.3%) contained complete nadA gene. All the 172 strains for which the nhba gene was sequenced had intact gene sequence which corresponded to 68 peptide types.@*Conclusion@#CC4821 was the predominant CC of MenB strains in China; the vaccine proteins were diverse about the sequences. The vaccine proteins should be carefully selected when developing MenB vaccines in China.

Babesia bovis: Actualidad del desarrollo de una vacuna / Babesia bovis: An Update on vaccine development / Babesia bovis: Atualidade do desenvolvimento de uma vacina

Introducción. Babesia bovis es el principal agente causal de la babesiosis bovina, una importante enfermedad veterinaria transmitida por garrapatas a nivel mundial. Las estrategias convencionales para controlar esta parasitosis han presentado múltiples limitaciones por lo que el desarrollo de una vacuna basada en antígenos representa una estrategia apropiada para la prevención y el tratamiento. Objetivo. Describir los aspectos relevantes del ciclo de vida del parásito B. bovis, la epidemiología, diagnóstico y la aplicación de diferentes estrategias usadas para controlar esta parasitosis. Además, se discuten potenciales puntos de intervención para desarrollar una vacuna contra este parásito. Metodología. Se realizó una búsqueda en las bases de datos usando los términos: "Babesia bovis AND lyfe cycle", "B. bovis vaccine and Vaccine candidates", entre otras. Los estudios con mayor pertinencia publicados hasta la actualidad se revisaron completamente. Resultados. Los detalles de la biología de parásito B. bovis y el proceso molecular usado para ocasionar la enfermedad en el hospedador son poco conocidos, lo que explica que el desarrollado de estrategias para el control de esta parasitosis no hayan sido del todo eficientes. Por lo tanto, se requiere diseñar nuevas medidas, por ejemplo, desarrollar vacunas de nueva generación basadas en un enfoque funcional que permitan mejorar las condiciones de sanidad animal. Conclusiones. Comprender el complejo ciclo de vida de B. bovis permitirá estudiar las interacciones huésped-parásito-garrapata e identificar moléculas implicadas en la adhesión/invasión celular para evaluar su utilidad como componente de una vacuna que controle esta parasitosis.

Introduction. Babesia bovis is the main causal agent of babesiosis bovine, one important veterinary diseases transmitted by ticks worldwide. Conventional strategies to control this parasitosis have shown several limitations and therefore the development of a vaccine will be an appropriate strategy for prevention and treatment. Objective. To describe relevant aspects of B. bovis parasite's life cycle, the epidemiology, diagnosis, the application of different strategies used to control this parasitosis. In addition, potential points of intervention to develop a vaccine against this parasite has been discussed. Methodology. A search was made using keywords as "Babesia bovis AND lyfe cycle", "B. bovis vaccine and Vaccine candidates" and others. The most relevant studies published to date were completely revised. Results. The details of the B.bovis parasite biology and the molecular process used to cause disease in the host had not been describe in deep; explaining that the development of strategies for the control of this parasitosis have not been entirely efficient. Therefore, it is necessary to design new procedures, for example, to develop new generation vaccines based on a functional approach which improve the animal health conditions. Conclusions. Understand the B. bovise's life cycle complex will allow the host-parasite-tick interactions study and the identification of molecules involved in cell adhesion / invasion to evaluate its usefulness as a vaccine component that controls this parasitosis.

Introdução. Babesia bovis é o principal agente causador da babesiose bovina, uma importante doença veterinária transmitida por carrapatos a nível mundial. As estratégias convencionais para o controle das parasitoses têm presentado múltiplas limitações pelo que o desenvolvimento de uma vacina baseada em antígenos representa uma estratégia apropriada para a prevenção e o tratamento. Objetivo. Descrever os aspectos relevantes do ciclo de vida do parasita B. bovis, a epidemiologia, diagnostico e aplicação de diferentes estratégias usadas para o controle desta parasitose. Além disso, são discutidos possíveis pontos de intervenção para o desenvolvimento de uma vacina contra o parasita. Metodologia. Uma pesquisa foi realizada nas bases de dados usando os termos: "Babesia bovis AND lyfe cycle", "B. bovis vaccine and Vaccine candidates", entre outras. Os estudos mais relevantes publicados até o momento foram completamente revisados. Resultados. Os detalhes da biologia do parasita B. bovis e o processo molecular usado para causar doenças no hospedeiro é pouco conhecido, o que explica que o desenvolvimento de estratégias para o controle desta parasitose não foram completamente eficientes. Portanto, é necessário projetar novas medidas, por exemplo, desenvolver vacinas de nova geração com base em uma abordagem funcional que permita melhorar as condições de saúde animal. Conclusões. Compreender o complexo ciclo de vida de B. bovis permitirá estudar as interações hospede­parasita­carrapatos e identificar moléculas envolvidas na adesão/invasão celular para avaliar sua utilidade como componente de uma vacina que controla essa parasitose.

Strategies for producing high-yield viral vaccine antigens / 生物工程学报

Vaccination is an important strategy to prevent infectious diseases. However, low antigen yield of vaccine producing strains may lead to high cost of vaccines, low antigen production and vaccine failure. In recent years, many efforts have been made to improve the antigen yield of many vaccines. This mini-review summarizes various methods for increasing the antigen yield for vaccine production, including genetic modification of viruses, improvement of the adaptation of viruses to cells, and optimization of antigen expression systems and manufacturing procedures. Furthermore, we discuss the advantages and the problems of current strategies, as well as indicate the perspectives.

Evaluation of adjuvant effects of fucoidan for improving vaccine efficacy

Fucoidan is a sulfated polysaccharide derived from brown seaweed, including Fucus vesiculosus. This compound is known to have immunostimulatory effects on various types of immune cells including macrophages and dendritic cells. A recent study described the application of fucoidan as a vaccine adjuvant. Vaccination is regarded as the most efficient prophylactic method for preventing harmful or epidemic diseases. To increase vaccine efficacy, effective adjuvants are needed. In the present study, we determined whether fucoidan can function as an adjuvant using vaccine antigens. Flow cytometric analysis revealed that fucoidan increases the expression of the activation markers major histocompatibility complex class II, cluster of differentiation (CD)25, and CD69 in spleen cells. In combination with Bordetella bronchiseptica antigen, fucoidan increased the viability and tumor necrosis factor-alpha production of spleen cells. Furthermore, fucoidan increased the in vivo production of antigen-specific antibodies in mice inoculated with Mycoplasma hyopneumoniae antigen. Overall, this study has provided valuable information about the use of fucoidan as a vaccine adjuvant.

Construction and Expression of an Eukaryotic Recombinant Plasmid from a Hybrid Gene of Antigen for Plasmodium falciparum / 中国寄生虫学与寄生虫病杂志

Objective To construct an eukaryotic recombinant plasmid with HGFSP, a hybrid gene encoding the antigen epitopes of MSA1, MSA2, RESA and CSP in different developing stages of Plasmodium falciparum(P.f. ). Methods HGFSP was sub-cloned into an eukaryotic expression plasmid pcDNA3 from a prokaryotic recombinant plasmid pSK-HGFSP to construct the eukaryotic recombinant expression plasmid pc-HGFSP. The identified recombinant was then transfected into HepG2 cells with liposome-mediated method. The G418-selected positive cell clones were tested to identify the immunogenicity of HGFSP-expressing antigen. Results It was evidenced that HGFSP was correctly inserted into pcDNA3 by restriction enzymes map analysis. HGFSP-expressing antigen-specific fluorescent response was observed in pc-HGFSP-transfected HepG2 cells. The results of SDS-PAGE and Western-blotting showed that there was a 23 kD protein band, which can be specifically recognized by anti-sera of HGFSP-expressing protein in pc-HGFSP-transfected HepG2 cell lysis. Conclusion Pc-HGFSP, an eukaryotic recombinant plasmid encoding hybrid antigen epitopes of P.f ., was constructed successfully and the antigenicity of pc-HGFSP-expressing protein was confirmed.